eflornithine has been researched along with Dysplastic Nevus Syndrome in 1 studies
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.
Dysplastic Nevus Syndrome: Clinically atypical nevi (usually exceeding 5 mm in diameter and having variable pigmentation and ill defined borders) with an increased risk for development of non-familial cutaneous malignant melanoma. Biopsies show melanocytic dysplasia. Nevi are clinically and histologically identical to the precursor lesions for melanoma in the B-K mole syndrome. (Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melanoma is a disease that need not be deadly." | 2.38 | The prevention of cutaneous malignant melanoma: high-risk groups, chemoprevention, education, and screening. ( Greene, MH, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Greene, MH | 1 |
1 review available for eflornithine and Dysplastic Nevus Syndrome
| Article | Year |
|---|---|
The prevention of cutaneous malignant melanoma: high-risk groups, chemoprevention, education, and screening.
Topics: Animals; Anticarcinogenic Agents; Dysplastic Nevus Syndrome; Eflornithine; Fluorouracil; Humans; Mas | 1993 |